Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | Promising future of PSMA for prostate cancer

Eugene Shenderov • 10 Jun 2022
ASCO 2022
Genitourinary Cancer Prostate Cancer
VISION

Eugene Shenderov, MD, PhD, Johns Hopkins Medicine, Baltimore, MD, discusses the hot topics in prostate cancer at ASCO 2022, including the development of immunotherapies and the rise of PSMA in the management of prostate cancer. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

More from Eugene Shenderov

6:57
Phase II trial of enoblituzumab for patients with intermediate/high-risk localised prostate cancer
Eugene Shenderov • 10 Jun 2022
3:50
Detection and risk stratification of localized prostate cancer
Eugene Shenderov • 17 Sep 2021
4:54
MGC018 in patients with advanced solid tumors
Eugene Shenderov • 17 Sep 2021
6:12
Neoadjuvant enoblituzumab for localized prostate cancer
Eugene Shenderov • 17 Sep 2021

Related Videos

4:05
Evaluating triplet therapy in metastatic hormone sensitive prostate cancer
Nick James • 24 Apr 2024
10:42
Management of prostate cancer from the patient perspective
David Matheson • 11 Apr 2024
2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals